Angewandte Chemie:新型探针有助可视化检测胶质瘤标志物

2020-05-12 中国科学报 中国科学报

日前,中国科学院院士黄维与南京工业大学教授李林团队、新加坡国立大学科研人员合作,设计合成了一种新的双光子荧光探针,这将有助于未来临床上对人源胶质瘤标志物(单胺氧化酶 A,即 MAO-A)进行可视化精准

日前,中国科学院院士黄维与南京工业大学教授李林团队、新加坡国立大学科研人员合作,设计合成了一种新的双光子荧光探针,这将有助于未来临床上对人源胶质瘤标志物(单胺氧化酶 A,即 MAO-A)进行可视化精准检测。其成果以热点文章的形式发表于《德国应用化学》。

据介绍,人体内的神经递质代谢需要维持稳定的代谢平衡,如果单胺氧化酶的功能发生异常,会过多或过少地代谢神经递质,从而破坏生物体内神经递质的代谢平衡。所以单胺氧化酶与中枢神经系统疾病有密切联系,是中枢神经系统疾病研究中的重要生化标志物。

李林表示,基于各自代谢底物的不同,单胺氧化酶分为两种亚型(MAO-A 和 MAO-B),MAO-A 和 MAO-B 就像一对孪生兄弟,它们的构造极其相似,两者氨基酸序列相似率高达 70% 以上。它们的功能异常与不同疾病有关。在帕金森氏症中,MAO-B 作为生化标志物,而 MAO-A 则作为胶质瘤标志物。如何使设计的分子探针具有更高的特异性、灵敏性,来精确区分这两者,从而助力胶质瘤和帕金森氏症这两类疾病标志物的特异性检测,是一项具有挑战以及生物学意义的工作。

在前期研究中,研究团队已经设计出了针对 MAO-B 特异性双光子荧光探针 U1。在 U1 的结构基础上,日前,该课题组又设计了一种新的 MAO-A 特异性双光子荧光探针 F1,通过探针与 MAO-A 反应后的荧光信号来判断检测物中 MAO-A 的活性,从而有助于实现对人源胶质瘤的标志物 MAO-A 进行可视化精准检测。

据悉,这一新的 MAO-A 探针将为胶质瘤和帕金森氏症这两种机制完全不同的中枢神经系统疾病的相关性研究提供有力研究工具。

原始出处:

Haixiao Fang Hang Zhang, et al. Rational Design of a Two‐Photon Fluorogenic Probe for Visualizing Monoamine Oxidase?A Activity in Human Glioma Tissues. Angewandte Chemie, 2020, 59(19), 7536-7541.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1841514, encodeId=3ff81841514bb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun May 24 22:11:25 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779940, encodeId=573c1e799404f, content=<a href='/topic/show?id=d8e32515d1' target=_blank style='color:#2F92EE;'>#Angew#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2515, encryptionId=d8e32515d1, topicName=Angew)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Sep 15 20:11:25 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942860, encodeId=a72b1942860ec, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Aug 26 11:11:25 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743943, encodeId=26041e4394329, content=<a href='/topic/show?id=8fcd566e89c' target=_blank style='color:#2F92EE;'>#探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56678, encryptionId=8fcd566e89c, topicName=探针)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f76635239744, createdName=lvygwyt2793, createdTime=Thu Jul 30 01:11:25 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1841514, encodeId=3ff81841514bb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun May 24 22:11:25 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779940, encodeId=573c1e799404f, content=<a href='/topic/show?id=d8e32515d1' target=_blank style='color:#2F92EE;'>#Angew#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2515, encryptionId=d8e32515d1, topicName=Angew)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Sep 15 20:11:25 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942860, encodeId=a72b1942860ec, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Aug 26 11:11:25 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743943, encodeId=26041e4394329, content=<a href='/topic/show?id=8fcd566e89c' target=_blank style='color:#2F92EE;'>#探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56678, encryptionId=8fcd566e89c, topicName=探针)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f76635239744, createdName=lvygwyt2793, createdTime=Thu Jul 30 01:11:25 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2020-09-15 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1841514, encodeId=3ff81841514bb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun May 24 22:11:25 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779940, encodeId=573c1e799404f, content=<a href='/topic/show?id=d8e32515d1' target=_blank style='color:#2F92EE;'>#Angew#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2515, encryptionId=d8e32515d1, topicName=Angew)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Sep 15 20:11:25 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942860, encodeId=a72b1942860ec, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Aug 26 11:11:25 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743943, encodeId=26041e4394329, content=<a href='/topic/show?id=8fcd566e89c' target=_blank style='color:#2F92EE;'>#探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56678, encryptionId=8fcd566e89c, topicName=探针)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f76635239744, createdName=lvygwyt2793, createdTime=Thu Jul 30 01:11:25 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1841514, encodeId=3ff81841514bb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun May 24 22:11:25 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779940, encodeId=573c1e799404f, content=<a href='/topic/show?id=d8e32515d1' target=_blank style='color:#2F92EE;'>#Angew#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2515, encryptionId=d8e32515d1, topicName=Angew)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Sep 15 20:11:25 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942860, encodeId=a72b1942860ec, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Aug 26 11:11:25 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743943, encodeId=26041e4394329, content=<a href='/topic/show?id=8fcd566e89c' target=_blank style='color:#2F92EE;'>#探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56678, encryptionId=8fcd566e89c, topicName=探针)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f76635239744, createdName=lvygwyt2793, createdTime=Thu Jul 30 01:11:25 CST 2020, time=2020-07-30, status=1, ipAttribution=)]

相关资讯

盘点:2020年度Radiology科研进展汇总(六)

Radiology:或许这才是靠谱体脂率测量的方法!

ONC201治疗胶质瘤的I / II期临床研究即将在日本开展

Oncoceutics制药公司宣布,ONC201已在临床前模型和多项正在进行的临床试验中证明了其抗胶质瘤的有效性和安全性。

疫路有我,阔然开朗:胶质瘤、脑转移瘤在线公益答疑

2020年3月14日,第一期“阔然专栏”在线直播栏目邀请复旦大学附属华山医院秦智勇教授、盛晓芳教授、梁晓华教授、庄冬晓教授和陈宏教授、徐州医科大学附属医院肿瘤中心章龙珍教授、复旦大学附属肿瘤医院曹依群

Nat Cell Bio:利用CRISPR技术精准修正胶质瘤致癌基因突变

研究人员使用腺相关病毒(Adeno-associated virus, AAV)作为载体表达拥有腺嘌呤脱氨酶活性的空肠弯曲菌(Campylobacter jejuni)Cas9融合蛋白以及对应的单向导RNA(sgRNA),实现精准修正胶质瘤细胞端粒酶基因启动子区域的致癌突变。

Radiology:IDH1突变胶质瘤在超高分辨率3D MR波谱下会有什么发现?

异柠檬酸脱氢酶(IDH)突变在胶质瘤中是非常常见的,会导致D- 2- 羟基戊二酸共代谢物(D-2HG)水平升高。因此,D-2HG水平可作为IDH突变胶质瘤非常有价值的影像学标记物。

陈忠平教授:2019年胶质瘤诊疗进展盘点

作为最常见的原发性颅内恶性肿瘤,胶质瘤是神经肿瘤领域最重要的瘤种,也是一个巨大的挑战。恶性胶质瘤约占所有胶质瘤的70%,治疗效果差,5年生存率仅在10%上下。近年,得益于基因组学、表观遗传学及肿瘤免疫学研究的深入,胶质瘤分子病理诊断与疗效评估以及新药物、新疗法的开发等方面均有颇多进展,以下对2019年度的诊疗进展进行盘点。诊断进展继IDH突变、1p19q共缺失及TERT突变等被引入WHO中枢神经系